Table 4.
Proportion Hospitalized or Died Between Day 4 and Day 28 by Anterior Nasal Severe Acute Respiratory Syndrome Coronavirus 2 RNA Results at Day 0 and Day 3
| Treatment Group | Day 0 AN SARS-CoV-2 RNA | Day 3 AN SARS-CoV-2 RNA | All | ||
|---|---|---|---|---|---|
| <LLoQ | 2–5.99 log10 Copies/mL | ≥6 log10 Copies/mL | |||
| Placebo only | <LLoQ | 0/123 (0.0%) | 1/8 (12.5%) | 0/5 (0.0%) | 1/136 (0.7%) |
| 2–5.99 log10 copies/mL | 4/83 (4.8%) | 3/132 (2.3%) | 1/10 (10.0%) | 8/225 (3.6%) | |
| ≥6 log10 copies/mL | 1/3 (33.3%) | 3/80 (3.8%) | 5/34 (14.7%) | 9/117 (7.7%) | |
| All | 5/209 (2.4%) | 7/220 (3.2%) | 6/49 (12.2%) | 18/478 (3.8%) | |
| mAb-treated only | <LLoQ | 1/231 (0.4%) | 0/12 (0.0%) | 0/2 (0.0%) | 1/245 (0.4%) |
| 2–5.99 log10 copies/mL | 2/331 (0.6%) | 1/307 (0.3%) | 0/6 (0.0%) | 3/644 (0.5%) | |
| ≥6 log10 copies/mL | 1/51 (2.0%) | 12/378 (3.2%) | 1/35 (2.9%) | 14/464 (3.0%) | |
| All | 4/613 (0.7%) | 13/697 (1.9%) | 1/43 (2.3%) | 18/1353 (1.3%) | |
| All participants | <LLoQ | 1/354 (0.3%) | 1/20 (5.0%) | 0/7 (0.0%) | 2/381 (0.5%) |
| 2–5.99 log10 copies/mL | 6/414 (1.4%) | 4/439 (0.9%) | 1/16 (6.3%) | 11/869 (1.3%) | |
| ≥6 log10 copies/mL | 2/54 (3.7%) | 15/458 (3.3%) | 6/69 (8.7%) | 23/581 (4.0%) | |
| All | 9/822 (1.1%) | 20/917 (2.2%) | 7/92 (7.6%) | 36/1831 (2.0%) | |
Data are presented as proportion (%). “<LLoQ” represents results below the lower limit of quantification (2 log10 copies/mL).
Abbreviations: AN, anterior nasal; LLoQ, lower limit of quantification; mAb, monoclonal antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.